ALLEVIATE-HF-HD Study

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

August 22, 2022

Study Completion Date

February 3, 2023

Conditions
Heart Failure
Interventions
DEVICE

ALV1System

The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.

Trial Locations (1)

Unknown

Tbilisi Heart and Vascular, Tbilisi

Sponsors
All Listed Sponsors
lead

Alleviant Medical, Inc.

INDUSTRY

NCT05501652 - ALLEVIATE-HF-HD Study | Biotech Hunter | Biotech Hunter